PARGY-LAD
propargyllysergic acid diethylamide
1Provenance card
the boundary, as counts
Sources
2520 with DOI
8 strong · 13 moderate · 4 weak
Compilations
22026-05-12T08:05:43.717Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09
Decisions
31last ruled 2026-06-04
0 awaiting a ruling
Issued documents
62026-10-19T20:33:29.141Z
notice · info card · emergency
Searches
00 with no results
queries and counts on the build
Claims checked
6034 supported
34 supported · 26 not
Correspondence
0received
consent field ships in Phase 4
Edges
193
derivations recorded for this entity
Complete over 25 sources, 2 compilations, and 31 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/pargy-lad/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-19issueIssued emergency
- 2026-10-19issueIssued info_card
- 2026-10-19issueIssued notice
- 2026-09-07srcReturn of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)
- 2026-09-07srcReturn of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)
- 2026-09-07srcAnalytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD
- 2026-09-07srcGenie in a blotter: A comparative study of LSD and LSD analogues' effects and user profile
- 2026-09-07srcA Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD
- 2026-09-07srcDesigner drugs: mechanism of action and adverse effects
- 2026-09-07srcThe toxicity of psychedelic LSD derivatives: in silico approach for 1cP-LSD and analogs
- 2026-09-07srcIn vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures
- 2026-09-07srcPharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
- 2026-09-07srcCrystal Structure of an LSD-Bound Human Serotonin Receptor
- 2026-09-07srcStructure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
- 2026-09-07srcThe polypharmacology of psychedelics reveals multiple targets for potential therapeutics
- 2026-09-07srcHallucinogen persisting perception disorder: what do we know after 50 years?
- 2026-09-07srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
- 2026-09-07srcSynthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives
- 2026-09-07srcMolecular design of a therapeutic LSD analogue with reduced hallucinogenic potential
- 2026-09-07srcHallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment
- 2026-09-07srcPharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects
- 2026-09-07srcPsychedelics
- 2026-09-07srcSerotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants?
- 2026-09-07srcPARGY-LAD PubChem Compound Entry
- 2026-09-07srcMonoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.
- 2026-09-07srcReports on PARGY-LAD (newly offered lysergamide) — Bluelight.org
- 2026-09-07srcPARGY-LAD — Wikipedia
- 2026-09-07srcPARGY-LAD — PsychonautWiki
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-05-12revisionRevision 1
- 2026-05-12genGeneration — pipeline-v5 · with 3 morepipeline-v5
- 2026-05-12rungeneration run
- 2026-05-11rungeneration run
The same entries, as forms: six forms.